Closely monitor patients with hepatic impairment for severe myelosuppressionĪBRAXANE is not recommended in patients who have a total bilirubin >5 x ULN or AST >10 x ULNįor MBC and NSCLC, the starting dose should be reduced for patients with moderate or severe hepatic impairmentįor pancreatic adenocarcinoma, ABRAXANE is not recommended for patients with moderate to severe hepatic impairment (total bilirubin >1.5 x ULN and AST ≤10 x ULN) The exposure and toxicity of paclitaxel can be increased in patients with hepatic impairment. Closely monitor patients with a previous history of hypersensitivity reaction to ABRAXANE with this drug Severe and sometimes fatal hypersensitivity reactions, including anaphylactic reactions, have been reportedĭo not rechallenge patients who experience a severe hypersensitivity reaction to ABRAXANE with this drugĬross-hypersensitivity between ABRAXANE and other taxane products has been reported and may include severe reactions such as anaphylaxis.
Monitor patients for signs and symptoms and interrupt ABRAXANE and gemcitabine during evaluation of suspected pneumonitis.Pneumonitis, including some cases that were fatal, occurred in 4% of patients receiving ABRAXANE in combination with gemcitabine.If a patient becomes febrile (regardless of ANC), initiate treatment with broad-spectrum antibioticsįor febrile neutropenia, interrupt ABRAXANE and gemcitabine until fever resolves and ANC ≥1500 cells/mm 3, then resume treatment at reduced dose levels Sepsis occurred in 5% of patients with or without neutropenia who received ABRAXANE in combination with gemcitabineīiliary obstruction or presence of biliary stent were risk factors for severe or fatal sepsis If ≥ Grade 3 sensory neuropathy develops, withhold ABRAXANE treatment until resolution to Grade 1 or 2 for MBC or until resolution to ≤ Grade 1 for NSCLC and pancreatic cancer followed by a dose reduction for all subsequent courses of ABRAXANE Sensory neuropathy is dose- and schedule-dependent Resume treatment with appropriate dose reduction if recommended In patients with adenocarcinoma of the pancreas, withhold ABRAXANE and gemcitabine if the ANC is less than 500 cells/mm 3 or platelets are less than 50,000 cells/mm 3 and delay initiation of the next cycle if the ANC is less than 1500 cells/mm 3 or platelet count is less than 100,000 cells/mm 3 on Day 1 of the cycle. In patients with NSCLC, resume treatment if recommended at permanently reduced doses for both weekly ABRAXANE and every-3-week carboplatin after ANC recovers to at least 1500 cells/mm 3 and platelet count of at least 100,000 cells/mm 3 on Day 1 or to an ANC of at least 500 cells/mm 3 and platelet count of at least 50,000 cells/mm 3 on Days 8 or 15 of the cycle Baseline neutrophil counts of 1500 cells/mm 3 and platelets recover to a level >100,000 cells/mm 3.Perform frequent complete blood cell counts on all patients receiving ABRAXANE Monitor for neutropenia, which may be severe and result in infection or sepsis. From now on, submit Pfizer Encompass Claim Form from home, workplace, or even on the go.Do not administer ABRAXANE therapy to patients who have baseline neutrophil counts of less than 1500 cells/mm 3 Consequently, you save hours (if not days or weeks) and eliminate additional payments.
Our service allows you to take the entire procedure of executing legal papers online. Double-check the entire document to ensure that you have not skipped anything.Go to the e-autograph tool to put an electronic signature on the template.Press the arrow with the inscription Next to move on from one field to another.Fill in the requested fields which are marked in yellow.Open the document in the full-fledged online editor by clicking Get form.The following tips will help you complete Pfizer Encompass Claim Form easily and quickly: Additionally, with us, all of the data you include in your Pfizer Encompass Claim Form is well-protected from loss or damage via industry-leading file encryption. Our templates are updated on a regular basis in accordance with the latest legislative changes. Business, tax, legal and other documents need a high level of protection and compliance with the law.
0 kommentar(er)
